Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia 30322, USA.
J Infect Dis. 2013 Sep;208(6):907-16. doi: 10.1093/infdis/jit276. Epub 2013 Jun 24.
Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae. Despite increasing prevalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for intermittent preventive treatment in pregnancy (IPTp).
Women without human immunodeficiency virus infection were enrolled upon delivery. Data on the number of SP doses received during pregnancy were recorded. The primary outcome was placental infection demonstrated by histologic analysis. Secondary outcomes included malaria parasitemia (in peripheral, placental, cord blood specimens) at delivery and composite birth outcome (small for gestational age, preterm delivery, or low birth weight). RESULTS.: Of 703 women enrolled, 22% received <2 SP doses. Receipt of ≥ 2 SP doses had no impact on histologically confirmed placental infection. IPTp-SP was associated with a dose-dependent protective effect on composite birth outcome in primigravidae, with an adjusted prevalence ratio of 0.50 (95% confidence interval [CI], .30-.82), 0.30 (95% CI, .19-.48), and 0.18 (95% CI, .05-.61) for 1, 2, and ≥ 3 doses, respectively, compared with 0 doses.
IPTp-SP did not reduce the frequency of placental infection but was associated with improved birth outcomes. Few women received no SP, so the true effect of IPTp-SP may be underestimated. Malawian pregnant women should continue to receive IPTp-SP, but alternative strategies and antimalarials for preventing malaria during pregnancy should be investigated.
孕妇疟疾与低出生体重和围产期死亡率增加有关,尤其是初产妇。尽管疟原虫对磺胺多辛-乙胺嘧啶(SP)的耐药性不断增加,但 SP 仍被推荐用于妊娠间歇性预防治疗(IPTp)。
在分娩时招募未感染人类免疫缺陷病毒的女性。记录怀孕期间接受的 SP 剂量数。主要结局是通过组织学分析证明胎盘感染。次要结局包括分娩时外周血、胎盘血和脐带血样本中的疟疾寄生虫血症以及复合出生结局(胎儿生长受限、早产或低出生体重)。
在纳入的 703 名女性中,有 22%的人接受了<2 剂 SP。接受≥2 剂 SP 对组织学证实的胎盘感染没有影响。IPTp-SP 与初产妇复合出生结局呈剂量依赖性保护作用相关,调整后的患病率比分别为 0.50(95%置信区间 [CI],0.30-0.82)、0.30(95%CI,0.19-0.48)和 0.18(95%CI,0.05-0.61),分别为 1、2 和≥3 剂,而 0 剂。
IPTp-SP 并未降低胎盘感染的频率,但与改善的出生结局相关。很少有女性未接受 SP,因此 IPTp-SP 的真实效果可能被低估。马拉维孕妇应继续接受 IPTp-SP,但应研究预防妊娠疟疾的替代策略和抗疟药物。